SRR13311184
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.610
- ANGIOGENESIS+0.480
- HEDGEHOG_SIGNALING+0.360
- KRAS_SIGNALING_UP+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- SPERMATOGENESIS+0.320
- COAGULATION+0.310
- ALLOGRAFT_REJECTION+0.290
- KRAS_SIGNALING_DN+0.220
- INFLAMMATORY_RESPONSE+0.190
Top 10 suppressed
- MYC_TARGETS_V2-0.570
- DNA_REPAIR-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.490
- MYC_TARGETS_V1-0.480
- OXIDATIVE_PHOSPHORYLATION-0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- PROTEIN_SECRETION-0.410
- P53_PATHWAY-0.380
- INTERFERON_ALPHA_RESPONSE-0.360
- TGF_BETA_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202435 | — | — | 0.958 |
| 2 | MNG1135 | — | — | 0.938 |
| 3 | SRR1334440 | GTEX | — | 0.932 |
| 4 | MNG1152 | — | — | 0.928 |
| 5 | MDT-AP-0225 | Med | Medulloblastoma | 0.923 |
| 6 | SRR1487295 | GTEX | — | 0.922 |
| 7 | SRR1486475 | GTEX | — | 0.921 |
| 8 | SRR12202400 | — | — | 0.918 |
| 9 | MNG1123 | — | — | 0.917 |
| 10 | SRR1416410 | GTEX | — | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.610 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.030 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |